insights_auto
Outlook: 30.3% bullish·0.0% bearish
Go to analysischevron_right
GILD:NASDAQ
Gilead Sciences, Inc
$146.85
arrow_upward
+1.82%(+2.62) 1D
$146.85
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 7, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GILD...
Open
$145.28
High
$148.60
Low
$144.85
Mkt. cap
182.09B
Avg. vol.
5.60M
Volume
5.10M
Dividend
2.23%
Quarterly dividend
$0.82
Ex-dividend date
Sep 15, 2026
52-wk high
$157.27
52-wk low
$114.02
EPS
-$2.66
Beta
0.32
Shares outstanding
1.24B
No. of employees
17K
Open
$145.28
High
$148.60
Low
$144.85
Mkt. cap
182.09B
Avg. vol.
5.60M
Volume
5.10M
Dividend
2.23%
Quarterly dividend
$0.82
Ex-dividend date
Sep 15, 2026
52-wk high
$157.27
52-wk low
$114.02
EPS
-$2.66
Beta
0.32
Shares outstanding
1.24B
No. of employees
17K
News stories
From web sources and news partners
News Corp
·
3 hours ago
Gilead Sciences Inc. stock outperforms competitors on strong trading day
GuruFocus
·
5 hours ago
GILD Maintained by JP Morgan -- Price Target Raised to $170
MarketBeat
·
6 hours ago
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Truist Financial Analyst Says
AD HOC NEWS
·
9 hours ago
Gilead Sciences stock gains 2.57 percent after AI agreement expands
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17K
FoundedJun 22, 1987
HeadquartersFoster City, California, United States
SectorBiotechnology
Websitegilead.com